EXOZ Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $4.35 and $18.40. With a market capitalization of about $57.27 million, eXoZymes, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.15). Key stats such as the average daily volume over the past year has been around 9.25 thousand shares, in line with its 52-week average. Headquartered in Monrovia, CA, eXoZymes, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Heltzen, the company employs approximately 32 people and listed since November 13, 2024. eXoZymes, Inc. operates as a development stage biotechnology company.

eXoZymes, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.21. This means the shares are trading above this model’s fair value.

EXOZ has shown mixed momentum, gaining 14.61% over the past week and -14.59% over the past quarter, though year-to-date performance is up 1.47%. Short-term trend indicators are bullishly aligned (SMA20 -11.06%, SMA50 -18.47%, SMA200 -25.95%). The stock’s 14-day RSI is 32.91 (weak momentum), while the ATR of 0.51 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.36% below its high and over 10.56% above its low. Average 10-day trading volume of 5.74 thousand shares is below the 3-month average of 9.27 thousand, indicating normal recent market interest.

eXoZymes, Inc. has 9.28 million shares outstanding. The public float is 7.20 million shares, elevated short interest at 0.44% of float. This equals 21.89 thousand shares. The short ratio is 1.6 days. Institutional investors hold 2.67% of the float. Insiders own 64.53%. Over the past six months, insider transactions show balanced activity. They sold 1.50 thousand shares across 2 transactions.

eXoZymes, Inc. trades at a P/E ratio of -5.65, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 16.07 reflecting a rich premium to book value. The P/FCF stands at -8.81, also below market averages. Compared to sector medians, eXoZymes, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that eXoZymes, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.43%, with price expected at $6.02 by September 24, 2026, within a range of $5.62 to $6.41 3-Month Outlook: Projected fall of -53.32%, reaching $2.88 by December 08, 2026, with a range of $2.17 to $3.31. 1-Year Outlook: Projected loss of -87.52%, with price at $0.77 by September 10, 2027, within a range of $0.09 to $0.85.

eXoZymes, Inc. (NASDAQ:EXOZ) shares are flat 1.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows eXoZymes, Inc. trading at a premium to the broader market with a P/E of -5.65. Our AI forecast model points to short-term weakness (-2.43% over two weeks), a medium-term fall (-53.32% over three months), and a longer-term loss (-87.52% over one year), with expected trading ranges indicating moderate volatility.